9 citations
,
May 2022 in “Drugs in Context” This report describes the successful use of sonidegib in treating two cases of locally advanced basal cell carcinoma, leading to remission in both instances, and reducing lesions in a patient with Gorlin syndrome, while noting mild side effects consistent with the drug's known profile.
September 2024 in “Dermatology Reports” In this study, 45 patients with advanced basal cell carcinoma treated with the medication sonidegib experienced a 24% incidence of alopecia, with detailed trichoscopic and LC-OCT examination revealing specific hair changes, suggesting LC-OCT might help identify early signs of alopecia from sonidegib use.
25 citations
,
January 2021 in “Journal of drugs in dermatology” This review reports that sonidegib and vismodegib, two Hedgehog inhibitors used for treating advanced basal cell carcinoma, have similar efficacy and safety profiles, but differ in pharmacokinetics, with sonidegib achieving peak concentration more rapidly and reaching steady state later than vismodegib.
February 2026 in “Dermatology and Therapy” This study observed that sonidegib led to a meaningful clinical response in a real-world Chinese cohort with locally advanced basal cell carcinoma, although pathological biopsy remains essential to confirm tumor clearance due to false positives in noninvasive assessments.
10 citations
,
June 2024 in “American Journal of Clinical Dermatology” This review highlights that while sonidegib and vismodegib offer promising treatment options for advanced basal cell carcinoma, their use is often limited by treatment-emergent adverse events, which can be managed through protocol modifications and supportive interventions.
